At Novel U Wellness, we understand the impact excessive sweating can have on your daily life. That’s why we offer effective Hyperhidrosis Treatments designed to help you regain control and confidence. Our experienced practitioners utilize the latest techniques and technologies to provide personalized solutions for managing excessive sweating.
Hyperhidrosis is a medical condition characterized by excessive sweating, often affecting the underarms, palms, and soles of the feet. Our treatments aim to reduce sweat production, providing relief from the emotional and social distress associated with this condition.
The treatment for hyperhidrosis involves the inhibition of nerve signals responsible for stimulating sweat gland activity.Our Hyperhidrosis Treatment process works by targeting the sweat glands, reducing their activity and minimizing excessive sweat production. We use a combination of advanced technologies and techniques to provide long-lasting results, helping you feel more comfortable and confident in your own skin.
Effective and Long-Lasting Results
Our treatments offer significant and long-lasting reductions in sweat production, helping you regain control and confidence. The duration of the results varies by individual and treated area, with effects typically lasting up to six months.
Both Neuromodulator injections and Radio Frequency Microneedling are non-surgical or minimally invasive, reducing the risk of complications and downtime. Clinical studies have demonstrated that Neuromodulator can reduce sweating by 82–87% in the underarms and 80–90% in the palms.
We offer a range of treatments to address hyperhidrosis in various areas, including underarms, hands, feet, and face.
At Novel U Wellness, we are committed to helping you find relief from hyperhidrosis and restoring your confidence and comfort. Schedule your consultation today to discuss how our hyperhidrosis treatments can benefit you.
Your journey begins with an in-depth consultation to discuss your concerns and evaluate your condition. This allows us to design a personalized treatment plan tailored to your needs.
During the procedure, our experienced practitioners will administer the chosen treatment, whether it be Neuromodulator injections, or Radio Frequency Microneedling
We provide detailed aftercare instructions to maximize your results and promote a quick recovery
Follow-up appointments are scheduled to monitor progress and address any questions you may have.
OnabotulinumtoxinA (Botox) injections are FDA-approved for severe primary axillary hyperhidrosis inadequately managed by topical agents, with robust clinical trial data demonstrating significant improvement in sweat reduction and patient-reported outcomes.
In a randomized, placebo-controlled trial of 320 adults with bilateral axillary hyperhidrosis, 91% of patients treated with Botox (50 Units per axilla) achieved at least a 50% reduction in axillary sweating at 4 weeks, compared to 36% in the placebo group .The median duration of response after the first injection was 201 days.Additional studies showed that 81–86% of patients receiving Botox (50 or 75 Units) had >50% reduction in sweat production, versus 41% with placebo, and 49–55% achieved a ≥2-grade improvement in the Hyperhidrosis Disease Severity Scale (HDSS), compared to 6% with placebo. There was no significant difference in efficacy between the 50 and 75 Unit doses.
Botox is FDA-approved for severe axillary hyperhidrosis in adults who have not responded to topical agents.The most common adverse events are mild and include injection site pain and localized muscle weakness.
These data support the use of onabotulinumtoxinA as an effective and durable treatment for axillary hyperhidrosis in appropriately selected patients.
Clinical trial data provide robust support for the use of onabotulinumtoxinA (Botox) injections in the management of severe axillary hyperhidrosis, particularly in patients unresponsive to topical therapies. A pivotal multicenter, randomized, double-blind, placebo-controlled trial demonstrated that intradermal botulinum toxin A significantly reduces sweat production and is well tolerated, with high patient satisfaction rates and sustained efficacy over several months.[3]
Landmark Study in Detail:
A landmark multicenter trial enrolled 145 patients with severe, refractory axillary hyperhidrosis to rigorously evaluate the efficacy and safety of intradermal botulinum toxin A. Each patient received 200 units of botulinum toxin A in one axilla and placebo in the other, with subsequent crossover to active treatment for the placebo side. The primary endpoint was the change in sweat production, measured gravimetrically.
Key findings included a dramatic reduction in sweat production: two weeks after injection, the mean sweat rate in the treated axilla dropped from 165 mg/min at baseline to 24 mg/min, compared to 144 mg/min in the placebo axilla .
In summary, this trial provides high-quality evidence that onabotulinumtoxinA is a safe, effective, and patient-preferred intervention for severe axillary hyperhidrosis, with benefits persisting for at least six months in most patients.
Beyond the pivotal randomized trial, additional high-quality evidence—including meta-analyses, systematic reviews, and studies in diverse hyperhidrosis subtypes—further substantiates the efficacy and safety of onabotulinumtoxinA for hyperhidrosis.
Recent meta-analyses confirm that botulinum toxin A injections produce significantly greater sweat reduction than placebo, with gravimetric measurements showing mean reductions of over 100 mg compared to controls, and improvements in disease severity and quality of life scores (HDSS and DLQI) consistently favoring treatment. These benefits are observed not only in axillary hyperhidrosis but also in palmar, plantar, and craniofacial forms, with studies reporting rapid onset (within 1–2 weeks) and durable effects lasting 4–8 months.
Comparative studies indicate that botulinum toxin A is at least as effective as other established treatments, with a lower incidence of adverse effects such as compensatory sweating or skin irritation. Quality-of-life improvements are substantial, with patients reporting reduced social and emotional burden and high satisfaction rates. Safety data from long-term and real-world studies show that adverse events are generally mild and transient, most commonly injection site pain or localized muscle weakness, and serious complications are rare.
In summary, the broader literature robustly supports the use of onabotulinumtoxinA for focal hyperhidrosis, demonstrating consistent efficacy, favorable safety, and meaningful improvements in patient-reported outcomes across multiple body sites and populations.
